Newsbenzinga
Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss
· Published
Article summary
Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways.
An excerpt from the original article.
Comments —
Loading comments…